Glaucoma PhysicianFDA Clears Wireless Pressure Goggles for Glaucoma

📋 Regulatory Action / Label Change

Balance Ophthalmics received 510(k) clearance for the wireless FSYX Ocular Pressure Adjusting Pump, a nonpharmacologic, nonsurgical goggle system applying overnight negative pressure to reduce nocturnal IOP. The HERCULES trial — 93 patients with normal-tension glaucoma, 52-week follow-up — reported 88.3% of treated eyes achieving at least 20% daytime IOP reduction versus 1.7% of controls, with mean nocturnal IOP falling from 20.4 to 12.4 mmHg.

Clinical Considerations

• Mean nocturnal IOP reduction of 39.1% in HERCULES with no serious adverse events; most common effects were transient lid and periorbital edema
• 88.3% of treated eyes achieved at least 20% daytime IOP reduction at 52 weeks versus 1.7% of fellow-eye controls
• Wireless connectivity enables ophthalmology practices to remotely monitor patient adherence and overnight usage data
• Device is intended as adjunctive therapy alongside existing pharmacologic and surgical glaucoma treatments, not as a standalone replacement

Practice Applications

• Consider FSYX as a potential adjunct for patients with open-angle glaucoma who show nocturnal IOP elevation or inadequate control on daytime therapies alone
• Recognize that HERCULES enrolled normal-tension glaucoma patients specifically; generalizability to broader open-angle glaucoma populations warrants evaluation
• Monitor Q4 2026 availability timeline and payer coverage determinations before integrating into practice planning
• Anticipate patient questions about at-home overnight device use; remote monitoring capability may support adherence counseling workflows